Skip to main content
Category

Uncategorized

bhi-logo

BioHealth Innovation, Inc. Bolsters Board of Directors

By Uncategorized

– Representatives from Sigma-Tau Pharmaceuticals Inc., Alexandria Real Estate Equities, Inc., and Deloitte Consulting LLP Take New Board Seats – 

– Charles Morton Becomes New Venable LLP Representative on Board while Mike Baader Stays on as Board Member (Now as Greenspring Associates Representative) –

bhi-logo

ROCKVILLE AND BALTIMORE, MARYLAND, August 11, 2014 – BioHealth Innovation, Inc. (BHI) announced today the appointment of four new members to its Board of Directors. Dave Lemus, Chief Executive Officer, Sigma-Tau Pharmaceuticals Inc.; Joel S. Marcus, Chairman, Chief Executive Officer, and Founder, Alexandria Real Estate Equities, Inc. (Alexandria Venture Investments); and Beth Meagher, Principal, Deloitte Consulting LLP, have joined the BHI Board of Directors, effective August 7, 2014, based upon their organizations’ newly committed support of BHI. Charles “Chuck” Morton now represents Venable LLP on the Board, as another new Board member, while Mike Baader, formerly with Venable, will continue to hold a seat on the Board, but now as a representative of Greenspring Associates. Cynthia L. Collins, CEO, Clarient, who had served on the BHI Board since early 2013, is stepping down from her Board position after relocating to the West Coast

“The expansion of and continued diversity within the BHI Board, based upon new key industry and service provider representatives who are all deeply involved in life sciences, is a testament to the positive impact BHI has made on the Central Maryland biohealth community to date,” said Richard Bendis, BHI President & CEO

“We look forward to the contributions from the new Board members representing these organizations. We’re also pleased to welcome a new Venable representative to the Board and that Mike Baader will continue to add value to the organization now that he is on the Greenspring Associates team,” said Douglas Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. “And, on behalf of the BHI staff and Board, I would also like to offer gratitude to Cynthia Collins for her service and contributions to the BHI Board over the last year and half.”

Read More
dave-lemus

Dave Lemus, CPA (Treasurer)

By Uncategorized

 Chief Operating Officer/Chief Financial Officer & Board Member, miRecule, Inc.

dave-lemus

 
Dave Lemus is an experienced C-Level executive (CEO-COO-CFO) and Non-Executive board member with extensive US & international business experience spanning over 20 years biotech in the biopharmaceutical industry, where he executed more than $3 billion in licensing, financing/capital markets and M&A transactions.
 
Additionally he also serves as a non-executive director on the boards of Sorrento Therapeutics (NASDAQ: SRNE), Silence Therapeutics plc (AIM: SLN), Celularity Inc., and the MIT Club Washington DC.  Previously he was CEO of Sigma Tau Pharmaceuticals Inc., and prior to this, CFO of MorphoSys AG, where he launched Germany’s first biotechnology IPO in 1999, having come from Hoffmann La Roche in Basel. 
 
He received his M.S. from the Massachusetts Institute of Technology, and B.S. from the University of Maryland, and is presently a C.P.A. in the state of Maryland.

 

joel-marcus

Joel S. Marcus

By Uncategorized

Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.joel-marcus

Joel S. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in urban innovation clusters. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in Series A capital and, as CEO from March 1997 to April 2018, has led its growth into an S&P 500 company with an approximately $18 billion total market capitalization and significant market presence in leading AAA locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In, 1996, Mr. Marcus founded Alexandria Venture Investments, the company’s venture arm, which provides strategic capital to transformative life science and technology companies.

Yaminah Leggett Wells

Yaminah Leggett-Wells

By Uncategorized

 Senior Director of Alliance Management at Amgen, Yaminah Leggett-WellsYaminah Leggett Wells

Yaminah Leggett-Wells serves as the Senior Director of Alliance Management at Amgen, overseeing global partnerships spanning all stages of drug development. With over 20 years of experience in the pharmaceutical industry, her expertise includes strategic leadership, clinical operations, business development, and project and alliance management.

charles-morton

Charles J. Morton, Jr. (Secretary)

By Uncategorized

Managing Partner, Venable

charles-morton

Chuck Morton, repeatedly ranked as one of the top M&A lawyers in the country,  Managing Partner of the Baltimore Office of Venable, Maryland’s largest law firm. He has a national practice, solving complex problems faced by lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses. He routinely advises on mergers and acquisitions and financings, including every flavor of equity investment. He regularly acts on behalf of private equity groups.  His practice focuses on life sciences and technology companies.

DoC Logo cmyk

Maryland Department of Commerce

By Uncategorized

www.commerce.maryland.gov

The Maryland Department of Commerce focuses on attracting, retaining, and expanding businesses and creating jobs in Maryland. The department will also place a renewed focus on better serving the diverse industries and geographic regions of the state, and marketing Maryland’s many assets to companies across the nation and abroad.

DoC Logo cmyk

 

 

 

roche

Roche

By Uncategorized

www.roche.com

Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics.

roche

 

 

 

astra zeneca logo

AstraZeneca

By Uncategorized

www.astrazeneca.com

Our scientific heritage is grounded in pushing the boundaries of small molecule discovery and development. For decades, our scientists have led the way in identifying the right chemical leads. Our early discovery and high throughput screening capabilities enable us to screen thousands of compounds a day to identify molecules with potential to inhibit or activate the target.

astra zeneca logo

 

 

 

New Enterprise Associates

By Uncategorized

www.nea.com

As one of the world’s largest and most active venture capital firms, NEA has developed deep domain expertise and insight into our industries of focus. We channel that knowledge into every technology and healthcare investment we make — at any stage, in any location, around the globe.

 

NEAlogo

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.